Valeria Baldivieso, MD

Valeria Baldivieso , MD

Medical Director Memory Care

Neuroscience

Valeria Baldivieso

Overview

Valeria C. Baldivieso Hurtado, MD, is a board-certified physician. After receiving her medical degree from the Autonomous University of Guadalajara, she completed an internship at Santa Maria Chapalita Hospital in Guadalajara, Mexico. Dr. Baldivieso also completed a Family Medicine Residency at Mayaguez Medical Center in Mayaguez, Puerto Rico and a Geriatric Medicine Fellowship at Jackson Memorial Hospital in Miami, Florida. A skilled and experienced researcher and practitioner, Dr. Baldivieso is fluent in English and Spanish, and focuses on senior memory care and well-being.

Articles

Implementation of digital cognitive assessment and blood Implementation of digital cognitive assessment and blood based biomarkers for early detection in Alzheimer's disease at Adventhealth: A Davos Alzheimer's collaborative flagship site

JOURNAL OF THE NEUROLOGICAL SCIENCES

2023

Nonmydriatic fundus camera for diabetic retinopathy screening in a safety net hospital: effectiveness, prevalence, and risk factors

EUROPEAN JOURNAL OF OPHTHALMOLOGY

2015

More Publication Information

Education & Training

Education

Autonomous University of Guadalajara

Residency

Mayaguez Medical Center in Mayaguez, Puerto Rico

Fellowship

Jackson Memorial Hospital in Miami, Florida

Associated Clinical Trials

NCT04639050

: BP42155: A Phase Ib/IIa, Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Patients With Prodromal or Mild to Moderate Alzheimer's Disease (Brainshuttle AD)

Icon for trial | BP42155 : BP42155: A Phase Ib/IIa, Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in P

This study is currently enrolling.

Trontinemab is an experimental drug that is being developed for the possible treatment of AD. Trontinemab combines an anti-amyloid antibody with a brain shuttle module which helps to deliver the antibody to the brain. It works ...

NCT06079190

A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared with Placebo in Patients with Early Alzheimer’s Disease

Icon for trial | AL101 A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared with Placebo in Patients with Early Alzheimer’s

This study is currently enrolling.

We are conducting this research study to find out if study drug GSK4527226 [AL101], a drug being developed by GSK together with another company called Alector, can reduce the loss of memory and decline in daily functioning usua ...